Text Size

Study In Patients With Dyslipidaemia

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00264667
First received: December 9, 2005
Last updated: August 27, 2009
Last verified: August 2009
History of Changes
  Purpose

Study in patients with dyslipidaemia.


Condition Intervention Phase
Dyslipidaemia
 Drug: GW677954
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Percentage change from baseline in non-HDL-C based on log-transformed data at week 24.

Secondary Outcome Measures:
  • Percentage change from baseline in lipids, in Homeostasis Model Assessment-insulin sensitivity (HOMA-S), C-Reactive Protein (CRP), Fasting Plasma Glucose (FPG), body weight and waist circumference.

Estimated Enrollment: 290
Study Start Date: December 2005
Intervention Details:
    Drug: GW677954
    Other Name: GW677954
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Waist circumference =102cm (men) or =88cm (women) at visit 1.
  • Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1.
  • Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1.
  • Subjects whose plasma LDL C concentration does not require treatment according to the NCEP ATP III guidelines at Screening Visit 1.

Exclusion Criteria:

  • History of diabetes
  • History of cardiovascular disease
  • Diagnosis of genetic lipid disorders
  • History of muscle pain
  • History of cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00264667

  Hide Study Locations
Locations
Argentina
GSK Investigational Site
Cordoba, Córdova, Argentina, 5000
GSK Investigational Site
Córdoba, Córdova, Argentina, 5000
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina, 1425
GSK Investigational Site
Cordoba, Argentina, 5016
GSK Investigational Site
San Juan, Argentina, 5400
Australia, Queensland
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
GSK Investigational Site
Meadowbrook, Queensland, Australia, 4131
Australia, South Australia
GSK Investigational Site
Elizabeth Vale, South Australia, Australia, 5112
GSK Investigational Site
Keswick, South Australia, Australia, 5035
Australia, Victoria
GSK Investigational Site
Camperdown, Victoria, Australia, 2050
Chile
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7510605
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7571831
Costa Rica
GSK Investigational Site
San Jose, Costa Rica
India
GSK Investigational Site
Ahmedabad, India, 380 052
GSK Investigational Site
Bangalore, India, 560034
GSK Investigational Site
Bangalore, India, 560 054
GSK Investigational Site
Chennai, India, 600 116
GSK Investigational Site
Mumbai, India, 400008
Latvia
GSK Investigational Site
Riga, Latvia, LV 1012
GSK Investigational Site
Riga, Latvia, LV1005
GSK Investigational Site
Riga, Latvia, LV1038
GSK Investigational Site
Riga, Latvia, LV 1002
Mexico
GSK Investigational Site
Pachuca, Hidalgo, Mexico, 42039
GSK Investigational Site
Guadalajara, Jalisco, Mexico, 44340
GSK Investigational Site
Durango, Mexico, 34000
GSK Investigational Site
Mexico, D.F., Mexico, 11650
New Zealand
GSK Investigational Site
Auckland, New Zealand, 1311
GSK Investigational Site
Christchurch, New Zealand, 8014
GSK Investigational Site
Rotorua, New Zealand, 3201
Pakistan
GSK Investigational Site
Karachi, Pakistan, 74800
GSK Investigational Site
Lahore, Pakistan, 54000
Romania
GSK Investigational Site
Brasov, Romania, 500366
GSK Investigational Site
Bucharest, Romania, 020045
GSK Investigational Site
Deva, Romania, 330084
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 111020
GSK Investigational Site
Moscow, Russian Federation, 101990
GSK Investigational Site
S.-Petresburg, Russian Federation, 195067
Slovakia
GSK Investigational Site
Kosice, Slovakia, 041 90
GSK Investigational Site
Kosice, Slovakia, 040 22
Spain
GSK Investigational Site
Alicante, Spain, 03114
GSK Investigational Site
Barcelona, Spain, 08022
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Granada, Spain, 18014
GSK Investigational Site
Granada, Spain, 18003
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Madrid, Spain, 28037
GSK Investigational Site
Santiago de Compostela, Spain, 15706
GSK Investigational Site
Tarrasa, Barcelona, Spain, 08221
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MA GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00264667     History of Changes
Other Study ID Numbers: ADG103440
Study First Received: December 9, 2005
Last Updated: August 27, 2009
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by GlaxoSmithKline:
Dyslipidaemia

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 16, 2013